Northbrook, IL 60062 -- (SBWIRE) -- 04/05/2023 -- The drug discovery services industry is expected to grow significantly in the near future, driven by advances in technology, increasing demand for new drugs, and a greater focus on drug safety. Companies are investing heavily in research and development to develop new drugs, and the drug discovery services industry is expected to benefit from this trend. Additionally, the increasing use of predictive analytics and artificial intelligence to develop drugs is expected to provide a further boost to the industry. As new and improved methods for drug discovery become available, the industry will continue to benefit from the advances in technology and the need for new drugs.

Drug Discovery Services Market in terms of revenue was estimated to be worth $20.6 billion in 2023 and is poised to reach $41.3 billion by 2028, growing at a CAGR of 14.9% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors such as growing R&D expenditure from pharmaceutical and biopharmaceutical companies, the increasing R&D pipeline creating a need for increased analytical testing outsourcing, initiatives for research on rare diseases and orphan drugs, and the high cost of in-house drug development are positively driving the growth of the drug discovery services market. Additionally, technological advancements, the introduction of new drug discovery techniques, the expiry of patents, and rising demand for specialized testing services among end users are expected to offer growth opportunities to players in this market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=138732129

Browse in-depth TOC on "Drug Discovery Services Market"

307 - Tables
54 - Figures
347 - Pages

The chemistry services segment accounted for the largest share of the type of segment in the drug discovery services market in 2022.

Based on type, the drug discovery services market is segmented into chemistry and biology services. The chemistry services segment commanded the largest share of this market in 2022. Growth in this market segment is mainly due to the vast application of chemistry services in multiple early drug development phases to deliver robust candidates for drug discovery. The capacious use of chemistry in academics & research institutes, biotechnology companies, and large scale pharmaceutical companies also support the market growth.

The biologics segment accounted for the fastest growing share of the drug type segment in the drug discovery services market in 2022.

Based on drug type the drug discovery services is segmented into small-molecule drugs and biologics. The fast growth of this segment can be attributed to increasing number of biologics in the pipeline, the increasing focus of biopharmaceutical companies on developing biologics for various therapeutic areas, the development of biologics, the high cost of biologics development, the complexity of the biologic drugs, and safety and manufacturing challenges associated with biologics are driving pharma biotech companies to outsource biologic drug discovery and development to experienced service providers.

The Asia Pacific region is the fastest-growing region of the drug discovery services market in 2022.

Based on the region, the drug discovery market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is estimated to register the highest growth during the forecast period primarily due to emerging middle class, rising government spending for pharmaceutical R&D, growing therapeutic area expertise, and rapid expansion of pharmaceutical and biopharmaceutical industry in the region.

Inquire Before Buying this Report:

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=138732129

Drug Discovery Services Market Dynamics:

Drivers:

Growing R&D expenditure in pharma-biotech sector
Increasing drug R&D pipeline and rising reliance on outsourcing
Initiatives for research on rare diseases and orphan drugs
High cost of in-house drug development

Restraints:

Stringent regulations governing drug discovery and animal usage

Opportunities:

Technological advancements and new drug discovery techniques
Rising demand for specialized testing services among end users
Patent expiries of key biologics
High growth prospects in emerging markets

Challenges:

Shortage of skilled personnel

Trends:

Adoption of AI in drug discovery
Increased outsourcing to emerging Asian economies
CRO industry consolidation
Integrated end-to-end R&D service offerings

Key Market Players:

Key players in the drug discovery service Market include Laboratory Corporation of America Holdings (US), Charles River Laboratories International Inc. (US), WuXi AppTec (China), and Thermo Fisher Scientific Inc (US).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=138732129